Lenz Therapeutics Inc.
07/02/2026 | Press release | Distributed by Public on 07/02/2026 15:02
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 30, 2026, Zach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation (the "Company") of his resignation as a member of the Company's Board of Directors (the "Board") and from all committees of the Board on which he served, effective immediately. Dr. Scheiner's resignation was not the result of any dispute or disagreement between the Company and Dr. Scheiner on any matter relating to the operations, policies or practices of the Company. Dr. Scheiner has been a valuable member of the Board and the Company expresses its appreciation for Dr. Scheiner's service and strong work as a member of the Board and the committees on which he served. On June 30, 2026, the Board decreased the size of the Board to six (6) as a result of Dr. Scheiner's resignation.
Following the resignation of Dr. Scheiner, on June 30, 2026, the Board appointed Jeff George to its audit committee (the "Audit Committee"). Effective upon such appointment, the members of the Audit Committee are Shelley Thunen, Frederic Guerard, and Jeff George.
Lenz Therapeutics Inc. published this content on July 02, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 02, 2026 at 21:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]